The effects of beraprost Na, a stable prostacyclin analog, on animal models of stroke
We evaluated the effects of beraprost Na (Sodium (+-)-(1R*,2R*, 3aS*,8bS*)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(E)-(3S*)-3- hyd roxy-4-methyl-1- octen-6-ynyl]-1H-cyclopenta[b]benzofuran-5-butylate, beraprost), a stable and orally active prostacyclin (PGI2) analog with potent antiplatelet and vasodilat...
Gespeichert in:
| Veröffentlicht in: | Molecular and chemical neuropathology 1992-08, Vol.17 (1), p.91-102 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 102 |
|---|---|
| container_issue | 1 |
| container_start_page | 91 |
| container_title | Molecular and chemical neuropathology |
| container_volume | 17 |
| creator | HIRANO, T YAMORI, Y KANAI, N UMETSU, T NISHIO, S |
| description | We evaluated the effects of beraprost Na (Sodium (+-)-(1R*,2R*, 3aS*,8bS*)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(E)-(3S*)-3- hyd roxy-4-methyl-1- octen-6-ynyl]-1H-cyclopenta[b]benzofuran-5-butylate, beraprost), a stable and orally active prostacyclin (PGI2) analog with potent antiplatelet and vasodilating properties, on two stroke models, namely sudden death induced by arachidonate (AA) in rabbits and spontaneous stroke in stroke-prone spontaneously hypertensive rats (SHRSP). In the AA-induced sudden death model, 30 min after beraprost administration (1 or 3 mg/kg, po), AA was injected into the rabbit internal carotid artery, and incidence of convulsion and sudden death were assessed. Beraprost decreased both incidence of convulsion and mortality of rabbits. In SHRSP, orally administered beraprost (100 micrograms/kg, twice a day from 56-385 d of age) improved survival rate and decreased incidence of stroke. Preventive effects of beraprost on the two stroke models may have been caused mainly by the improvement of cerebral circulation. These results indicate that beraprost may have potential in the treatment and/or prevention of the cerebral circulatory disorders. |
| doi_str_mv | 10.1007/bf03159984 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1007_BF03159984</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1388452</sourcerecordid><originalsourceid>FETCH-LOGICAL-c377t-339b10fd63b9dab4d46d6369c414603a63acb4bc9569d7e58014b892837a303a3</originalsourceid><addsrcrecordid>eNpFkL1PwzAQxS0EKqWwsCN5YEIN2DnHHyNUFJAqWNo5Ojs2FNKmssPQ_560KTDd073fnZ4eIZec3XLG1J0NDHhhjBZHZJhzqTOtcnNMhpwJkSkwcErOUvpkTOag8wEZcNBaFPmQLOYfnvoQvGsTbQK1PuImNqmlrzimSFOLtvZ0v0K3dfVyTXGNdfM-ps1OLldY01VT-Xp_n9rYfPlzchKwTv7iMEdkMX2cT56z2dvTy-R-ljlQqs0AjOUsVBKsqdCKSshOS-MEF5IBSkBnhXWmkKZSvtCMC6tNrkEhdD6MyE3_13X5UvSh3MQuUNyWnJW7asqH6W81HXzVw5tvu_LVP9p30fnXBx-TwzpEXLtl-sMEGMYlwA8PVmnc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>The effects of beraprost Na, a stable prostacyclin analog, on animal models of stroke</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>HIRANO, T ; YAMORI, Y ; KANAI, N ; UMETSU, T ; NISHIO, S</creator><creatorcontrib>HIRANO, T ; YAMORI, Y ; KANAI, N ; UMETSU, T ; NISHIO, S</creatorcontrib><description>We evaluated the effects of beraprost Na (Sodium (+-)-(1R*,2R*, 3aS*,8bS*)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(E)-(3S*)-3- hyd roxy-4-methyl-1- octen-6-ynyl]-1H-cyclopenta[b]benzofuran-5-butylate, beraprost), a stable and orally active prostacyclin (PGI2) analog with potent antiplatelet and vasodilating properties, on two stroke models, namely sudden death induced by arachidonate (AA) in rabbits and spontaneous stroke in stroke-prone spontaneously hypertensive rats (SHRSP). In the AA-induced sudden death model, 30 min after beraprost administration (1 or 3 mg/kg, po), AA was injected into the rabbit internal carotid artery, and incidence of convulsion and sudden death were assessed. Beraprost decreased both incidence of convulsion and mortality of rabbits. In SHRSP, orally administered beraprost (100 micrograms/kg, twice a day from 56-385 d of age) improved survival rate and decreased incidence of stroke. Preventive effects of beraprost on the two stroke models may have been caused mainly by the improvement of cerebral circulation. These results indicate that beraprost may have potential in the treatment and/or prevention of the cerebral circulatory disorders.</description><identifier>ISSN: 1044-7393</identifier><identifier>EISSN: 2168-8729</identifier><identifier>DOI: 10.1007/bf03159984</identifier><identifier>PMID: 1388452</identifier><language>eng</language><publisher>Totowa, NJ: Humana Press</publisher><subject>Animals ; Antianginal agents. Coronary vasodilator agents ; Arachidonic Acid ; Biological and medical sciences ; Blood Pressure - drug effects ; Body Weight - drug effects ; Cardiovascular system ; Cerebrovascular Circulation - drug effects ; Cerebrovascular Disorders - chemically induced ; Cerebrovascular Disorders - drug therapy ; Cerebrovascular Disorders - mortality ; Death, Sudden ; Diltiazem - therapeutic use ; Epoprostenol - analogs & derivatives ; Epoprostenol - pharmacology ; Male ; Medical sciences ; Pharmacology. Drug treatments ; Platelet Aggregation Inhibitors - pharmacology ; Rabbits ; Rats ; Rats, Inbred SHR ; Ticlopidine - therapeutic use</subject><ispartof>Molecular and chemical neuropathology, 1992-08, Vol.17 (1), p.91-102</ispartof><rights>1993 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c377t-339b10fd63b9dab4d46d6369c414603a63acb4bc9569d7e58014b892837a303a3</citedby><cites>FETCH-LOGICAL-c377t-339b10fd63b9dab4d46d6369c414603a63acb4bc9569d7e58014b892837a303a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=4390163$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1388452$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>HIRANO, T</creatorcontrib><creatorcontrib>YAMORI, Y</creatorcontrib><creatorcontrib>KANAI, N</creatorcontrib><creatorcontrib>UMETSU, T</creatorcontrib><creatorcontrib>NISHIO, S</creatorcontrib><title>The effects of beraprost Na, a stable prostacyclin analog, on animal models of stroke</title><title>Molecular and chemical neuropathology</title><addtitle>Mol Chem Neuropathol</addtitle><description>We evaluated the effects of beraprost Na (Sodium (+-)-(1R*,2R*, 3aS*,8bS*)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(E)-(3S*)-3- hyd roxy-4-methyl-1- octen-6-ynyl]-1H-cyclopenta[b]benzofuran-5-butylate, beraprost), a stable and orally active prostacyclin (PGI2) analog with potent antiplatelet and vasodilating properties, on two stroke models, namely sudden death induced by arachidonate (AA) in rabbits and spontaneous stroke in stroke-prone spontaneously hypertensive rats (SHRSP). In the AA-induced sudden death model, 30 min after beraprost administration (1 or 3 mg/kg, po), AA was injected into the rabbit internal carotid artery, and incidence of convulsion and sudden death were assessed. Beraprost decreased both incidence of convulsion and mortality of rabbits. In SHRSP, orally administered beraprost (100 micrograms/kg, twice a day from 56-385 d of age) improved survival rate and decreased incidence of stroke. Preventive effects of beraprost on the two stroke models may have been caused mainly by the improvement of cerebral circulation. These results indicate that beraprost may have potential in the treatment and/or prevention of the cerebral circulatory disorders.</description><subject>Animals</subject><subject>Antianginal agents. Coronary vasodilator agents</subject><subject>Arachidonic Acid</subject><subject>Biological and medical sciences</subject><subject>Blood Pressure - drug effects</subject><subject>Body Weight - drug effects</subject><subject>Cardiovascular system</subject><subject>Cerebrovascular Circulation - drug effects</subject><subject>Cerebrovascular Disorders - chemically induced</subject><subject>Cerebrovascular Disorders - drug therapy</subject><subject>Cerebrovascular Disorders - mortality</subject><subject>Death, Sudden</subject><subject>Diltiazem - therapeutic use</subject><subject>Epoprostenol - analogs & derivatives</subject><subject>Epoprostenol - pharmacology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Platelet Aggregation Inhibitors - pharmacology</subject><subject>Rabbits</subject><subject>Rats</subject><subject>Rats, Inbred SHR</subject><subject>Ticlopidine - therapeutic use</subject><issn>1044-7393</issn><issn>2168-8729</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1992</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkL1PwzAQxS0EKqWwsCN5YEIN2DnHHyNUFJAqWNo5Ojs2FNKmssPQ_560KTDd073fnZ4eIZec3XLG1J0NDHhhjBZHZJhzqTOtcnNMhpwJkSkwcErOUvpkTOag8wEZcNBaFPmQLOYfnvoQvGsTbQK1PuImNqmlrzimSFOLtvZ0v0K3dfVyTXGNdfM-ps1OLldY01VT-Xp_n9rYfPlzchKwTv7iMEdkMX2cT56z2dvTy-R-ljlQqs0AjOUsVBKsqdCKSshOS-MEF5IBSkBnhXWmkKZSvtCMC6tNrkEhdD6MyE3_13X5UvSh3MQuUNyWnJW7asqH6W81HXzVw5tvu_LVP9p30fnXBx-TwzpEXLtl-sMEGMYlwA8PVmnc</recordid><startdate>19920801</startdate><enddate>19920801</enddate><creator>HIRANO, T</creator><creator>YAMORI, Y</creator><creator>KANAI, N</creator><creator>UMETSU, T</creator><creator>NISHIO, S</creator><general>Humana Press</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>19920801</creationdate><title>The effects of beraprost Na, a stable prostacyclin analog, on animal models of stroke</title><author>HIRANO, T ; YAMORI, Y ; KANAI, N ; UMETSU, T ; NISHIO, S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c377t-339b10fd63b9dab4d46d6369c414603a63acb4bc9569d7e58014b892837a303a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1992</creationdate><topic>Animals</topic><topic>Antianginal agents. Coronary vasodilator agents</topic><topic>Arachidonic Acid</topic><topic>Biological and medical sciences</topic><topic>Blood Pressure - drug effects</topic><topic>Body Weight - drug effects</topic><topic>Cardiovascular system</topic><topic>Cerebrovascular Circulation - drug effects</topic><topic>Cerebrovascular Disorders - chemically induced</topic><topic>Cerebrovascular Disorders - drug therapy</topic><topic>Cerebrovascular Disorders - mortality</topic><topic>Death, Sudden</topic><topic>Diltiazem - therapeutic use</topic><topic>Epoprostenol - analogs & derivatives</topic><topic>Epoprostenol - pharmacology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Platelet Aggregation Inhibitors - pharmacology</topic><topic>Rabbits</topic><topic>Rats</topic><topic>Rats, Inbred SHR</topic><topic>Ticlopidine - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>HIRANO, T</creatorcontrib><creatorcontrib>YAMORI, Y</creatorcontrib><creatorcontrib>KANAI, N</creatorcontrib><creatorcontrib>UMETSU, T</creatorcontrib><creatorcontrib>NISHIO, S</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Molecular and chemical neuropathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>HIRANO, T</au><au>YAMORI, Y</au><au>KANAI, N</au><au>UMETSU, T</au><au>NISHIO, S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The effects of beraprost Na, a stable prostacyclin analog, on animal models of stroke</atitle><jtitle>Molecular and chemical neuropathology</jtitle><addtitle>Mol Chem Neuropathol</addtitle><date>1992-08-01</date><risdate>1992</risdate><volume>17</volume><issue>1</issue><spage>91</spage><epage>102</epage><pages>91-102</pages><issn>1044-7393</issn><eissn>2168-8729</eissn><abstract>We evaluated the effects of beraprost Na (Sodium (+-)-(1R*,2R*, 3aS*,8bS*)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(E)-(3S*)-3- hyd roxy-4-methyl-1- octen-6-ynyl]-1H-cyclopenta[b]benzofuran-5-butylate, beraprost), a stable and orally active prostacyclin (PGI2) analog with potent antiplatelet and vasodilating properties, on two stroke models, namely sudden death induced by arachidonate (AA) in rabbits and spontaneous stroke in stroke-prone spontaneously hypertensive rats (SHRSP). In the AA-induced sudden death model, 30 min after beraprost administration (1 or 3 mg/kg, po), AA was injected into the rabbit internal carotid artery, and incidence of convulsion and sudden death were assessed. Beraprost decreased both incidence of convulsion and mortality of rabbits. In SHRSP, orally administered beraprost (100 micrograms/kg, twice a day from 56-385 d of age) improved survival rate and decreased incidence of stroke. Preventive effects of beraprost on the two stroke models may have been caused mainly by the improvement of cerebral circulation. These results indicate that beraprost may have potential in the treatment and/or prevention of the cerebral circulatory disorders.</abstract><cop>Totowa, NJ</cop><pub>Humana Press</pub><pmid>1388452</pmid><doi>10.1007/bf03159984</doi><tpages>12</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1044-7393 |
| ispartof | Molecular and chemical neuropathology, 1992-08, Vol.17 (1), p.91-102 |
| issn | 1044-7393 2168-8729 |
| language | eng |
| recordid | cdi_crossref_primary_10_1007_BF03159984 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Animals Antianginal agents. Coronary vasodilator agents Arachidonic Acid Biological and medical sciences Blood Pressure - drug effects Body Weight - drug effects Cardiovascular system Cerebrovascular Circulation - drug effects Cerebrovascular Disorders - chemically induced Cerebrovascular Disorders - drug therapy Cerebrovascular Disorders - mortality Death, Sudden Diltiazem - therapeutic use Epoprostenol - analogs & derivatives Epoprostenol - pharmacology Male Medical sciences Pharmacology. Drug treatments Platelet Aggregation Inhibitors - pharmacology Rabbits Rats Rats, Inbred SHR Ticlopidine - therapeutic use |
| title | The effects of beraprost Na, a stable prostacyclin analog, on animal models of stroke |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T07%3A53%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20effects%20of%20beraprost%20Na,%20a%20stable%20prostacyclin%20analog,%20on%20animal%20models%20of%20stroke&rft.jtitle=Molecular%20and%20chemical%20neuropathology&rft.au=HIRANO,%20T&rft.date=1992-08-01&rft.volume=17&rft.issue=1&rft.spage=91&rft.epage=102&rft.pages=91-102&rft.issn=1044-7393&rft.eissn=2168-8729&rft_id=info:doi/10.1007/bf03159984&rft_dat=%3Cpubmed_cross%3E1388452%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/1388452&rfr_iscdi=true |